Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.53 |
| ▸ | NOS1 | P29475 | 1/20 | 0.53 |
| ▸ | NOS2 | P35228 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11669399 | 0.98 | NOS3 (0.51) | NOS3NOS1NOS2POLBTAAR1 | |
| SCHEMBL11669280 | 0.98 | NOS3 (0.51) | NOS3NOS1NOS2POLBTAAR1 | |
| SCHEMBL5654987 | 0.94 | NOS3 (0.54) | NOS3NOS1NOS2POLBTAAR1 | |
| SCHEMBL52608 | 0.94 | NOS3 (0.54) | NOS3NOS1NOS2POLBTAAR1 | |
| SCHEMBL1830037 | 0.84 | NOS3 (0.50) | NOS3NOS1NOS2POLBTAAR1 | |
| SCHEMBL4953597 | 0.83 | TRPA1 (0.44) | NOS3NOS1NOS2MAPT | |
| SCHEMBL3169716 | 0.81 | TRPA1 (0.44) | NOS3NOS1NOS2POLBRAB9A | |
| SCHEMBL1968440 | 0.81 | SLC18A2 (0.49) | TAAR1 | |
| SCHEMBL3168892 | 0.80 | ALDH1A1 (0.41) | TAAR1SMN1; SMN2 | |
| SCHEMBL8946022 | 0.79 | TAAR1 (0.49) | TAAR1ADRA2AADRA2BADRA2CSLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 420 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110143978-B | Metal organic complex with asymmetric structure and binuclear structure as well as preparation and application thereof | 太原理工大学 | 2020-07-24 | — | — | CN | claimed |
| EP-2718280-B1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMA SPA (IT) | 2015-09-16 | — | — | EP | claimed |
| US-8877774-B2 | Compounds having muscarinic receptor antagonist and beta2 Adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-11-04 | — | — | US | claimed |
| EP-2588458-B1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-06-04 | — | — | EP | claimed |
| EP-2718280-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | Chiesi Farmaceutici S.p.A. (IT) | 2014-04-16 | — | — | EP | claimed |
| US-8592594-B2 | Tetrahydro-quinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-11-26 | — | — | US | claimed |
| US-20130045169-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-02-21 | — | — | US | claimed |
| WO-2012168359-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-12-13 | — | — | WO | claimed |
| EP-1988081-B1 | BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE | TAISHO PHARMACEUTICAL CO LTD (JP) | 2012-10-17 | — | — | EP | claimed |
| US-20120004218-A1 | NOVEL TETRAHYDRO-QUINOLINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-01-05 | — | — | US | claimed |
| CN-1141297-A | Pyrazolopyrimidines and pyrrolopyrimidines for treatment of neuronal and other disorders | PFIZER (US) | 1997-01-29 | — | — | CN | claimed |
| US-5576335-A | TREATMENT OF HYPERCHOLESTEROLEMIA AND ATHEROSCLEROSIS | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1996-11-19 | — | — | US | claimed |
| EP-0729758-A2 | Pyrazolopyrimidines and pyrrolopyrimidines for treatment of neuronal and other disorders | PFIZER INC. (US) | 1996-09-04 | — | — | EP | claimed |
| EP-0543919-B1 | USE OF HETEROCYCLIC AMINO-ALCOHOL COMPOUNDS IN THE MANUFACTURE OF A MEDICAMENT FOR TREATMENT OF CNS DISEASES | SEARLE & CO (US) | 1996-04-10 | — | — | EP | claimed |
| EP-0665216-A1 | Urea derivatives and their use as acat inhibitors | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1995-08-02 | — | — | EP | claimed |
| EP-0543919-A1 | USE OF HETEROCYCLIC AMINO-ALCOHOL COMPOUNDS FOR TREATMENT OF CNS DISEASES. | SEARLE & CO (US) | 1993-06-02 | — | — | EP | claimed |
| WO-1992003131-A1 | USE OF HETEROCYCLIC AMINO-ALCOHOL COMPOUNDS FOR TREATMENT OF CNS DISEASES | G.D. SEARLE & CO. (US) | 1992-03-05 | — | — | WO | claimed |
| EP-0106275-B1 | 1,4-DIHYDROPYRIDINE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1991-03-13 | — | — | EP | claimed |
| EP-0106275-A2 | 1,4-Dihydropyridine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1984-04-25 | — | — | EP | claimed |
| US-4016263-A | BACTERICIDES | BOEHRINGER INGELHEIM GMBH (DT) | 1977-04-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045169-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2B | NOS3 1352/4885NOS1 1100/4885NOS2 649/4885 |
| US-20120004218-A1 | NOVEL TETRAHYDRO-QUINOLINE DERIVATIVES | GPR119, PRKAB1, PRKAG1 | NOS3 334/4885NOS1 115/4885NOS2 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.